Guardant Health Revenue 2017-2021 | GH

Guardant Health annual/quarterly revenue history and growth rate from 2017 to 2021. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
  • Guardant Health revenue for the quarter ending September 30, 2021 was $0.095B, a 27.1% increase year-over-year.
  • Guardant Health revenue for the twelve months ending September 30, 2021 was $0.344B, a 26.74% increase year-over-year.
  • Guardant Health annual revenue for 2020 was $0.287B, a 33.75% increase from 2019.
  • Guardant Health annual revenue for 2019 was $0.214B, a 136.52% increase from 2018.
  • Guardant Health annual revenue for 2018 was $0.091B, a 81.85% increase from 2017.
Guardant Health Annual Revenue
(Millions of US $)
2020 $287
2019 $214
2018 $91
2017 $50
2016 $25
Guardant Health Quarterly Revenue
(Millions of US $)
2021-09-30 $95
2021-06-30 $92
2021-03-31 $79
2020-12-31 $78
2020-09-30 $75
2020-06-30 $66
2020-03-31 $68
2019-12-31 $63
2019-09-30 $61
2019-06-30 $54
2019-03-31 $37
2018-12-31 $33
2018-09-30 $22
2018-06-30 $19
2018-03-31 $17
2017-12-31
2017-09-30 $11
2016-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $7.396B $0.287B
Guardant Health Inc. is a precision oncology company. It focuses on conquer cancer through use of proprietary blood tests, vast data sets and advanced analytics. The company's Guardant Health Oncology Platform is designed for clinical development, regulatory and reimbursement to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs. It launched multiple liquid biopsy-based tests, Guardant360 and GuardantOMNI, for advanced stage cancer patients, which fuel its development programs for recurrence and early detection, LUNAR-1 and LUNAR-2. Guardant Health Inc. is based in REDWOOD CITY, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $143.345B 9.06
Bio-Rad Laboratories (BIO.B) United States $18.101B 36.73
QIAGEN (QGEN) Netherlands $11.301B 19.14
Biohaven Pharmaceutical Holding (BHVN) United States $7.598B 0.00
Emergent Biosolutions (EBS) United States $2.503B 9.00
Arcus Biosciences (RCUS) United States $2.274B 0.00
Myovant Sciences (MYOV) United Kingdom $1.296B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.081B 0.00
Zymeworks (ZYME) Canada $0.538B 0.00
SQZ Biotechnologies (SQZ) United States $0.203B 0.00
Ambrx Biopharma (AMAM) United States $0.201B 0.00
Enzo Biochem (ENZ) United States $0.155B 20.00